NVO logo

Novo Nordisk A/S (NVO)

$37.82

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NVO

Market cap

$167.46B

EPS

3.62

P/E ratio

10.8

Price to sales

3.57

Dividend yield

3.06%

Beta

0.694454

Price on NVO

Previous close

$38.87

Today's open

$38.44

Day's range

$37.75 - $39.12

52 week range

$35.12 - $64.16

Profile about NVO

CEO

Maziar Mike Doustdar

Employees

66700

Headquarters

Bagsvaerd,

Exchange

New York Stock Exchange

Shares outstanding

4.43B

Issue type

American Depository Receipt

NVO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NVO

Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

Novo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly. Given the size of the weight-loss market, there's likely to be room for more than one GLP-1 maker.

news source

The Motley Fool • 10 hours ago

news preview

Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient Investors

Eli Lilly's not the only GLP-1 game in town -- Novo Nordisk has an oral pill formulation. The company's shares are attractive, and the company is poised to grow.

news source

The Motley Fool • Nov 20, 2026

news preview

GLP-1 drugs tied to heart improvements in patients with obesity and heart failure

The benefits of widely used GLP-1 medications beyond weight loss continue to pile up as evidenced by a series of studies we cover ​today that were presented at the Obesity Week 2026, opens new tab medical meeting in Washington.

news source

Reuters • Nov 20, 2026

news preview

Novo Nordisk: A Return To Growth May Be Just Around The Corner

I maintain a Buy on Novo Nordisk A/S: a 10–11 forward P/E looks inexpensive given potential returning to growth. Two quarterly beats and raised guidance support modest NVO 2026 growth; stronger-than-expected 2027 guidance could help NVO regain momentum. I see CagriSema approval and a successful launch as critical to NVO closing the efficacy gap with Lilly and establishing an amylin first-mover advantage.

news source

Seeking Alpha • Nov 19, 2026

news preview

Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says

The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats ​and rising uptake among men accelerate their use, researcher ‌Worldpanel by Numerator said on Thursday.

news source

Reuters • Nov 19, 2026

news preview

Novo Nordisk: The Worst May Be Behind

Novo Nordisk A/S remains a long-term Buy: its wide moat and falling capital expenditure support higher free cash flow. NVO raised 2026 free cash flow guidance to DKK 60–70 billion while guiding for adjusted sales and operating profit between a 2% decline and 2% growth. NVO's Wegovy pill and pipeline diversification support growth, although competition, pricing pressure, and semaglutide's 2032 patent expiration threaten sales.

news source

Seeking Alpha • Nov 18, 2026

news preview

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.

Johnson & Johnson currently exhibits a stronger overall position by generating a substantially larger total revenue volume than Novo Nordisk. Johnson & Johnson maintained a consistent quarter-over-quarter upward trajectory, while Novo Nordisk reported mostly flat U.S. dollar figures with the exception of one isolated spike.

news source

The Motley Fool • Nov 17, 2026

news preview

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

Eli Lilly has achieved explosive revenue growth fueled by its expanding portfolio of next-generation metabolic and weight-loss drugs. Novo Nordisk maintains a deep global reach with established diabetes and obesity treatments currently available in more than 50 countries.

news source

The Motley Fool • Nov 17, 2026

news preview

Novo Nordisk: The Thesis Is Working, The Stock Just Hasn't Noticed Yet

I retain a Strong Buy on Novo Nordisk: improving cash flow and cost discipline reinforce an inexpensive valuation at 10.89 times non-GAAP earnings. NVO raised free cash flow guidance to DKK 60–70 billion after generating DKK 28.4 billion in Q3; gross margin rose to 82.1%. NVO's obesity pill is scaling internationally, while CagriSema's lower-dose data and expected FDA decision support a credible path toward an early 2027 launch.

news source

Seeking Alpha • Nov 17, 2026

news preview

Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval

The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.

news source

WSJ • Nov 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Novo Nordisk A/S

Open an M1 investment account to buy and sell Novo Nordisk A/S commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NVO on M1